Thirty-three new projects are being funded as part of the Foundation's $100 million Infection Research Initiative.
Site Search
The U.S. Food and Drug Administration has approved the use of ivacaftor (Kalydeco®) for children as young as 6 months.
The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help mucus become more hydrated and easier to clear from the lungs of all people with CF, regardless of their CFTR mutations.
The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.
Multiple Principal Investigator Clinical Awards are offered to provide support for multi-investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation’s mission.
The Cystic Fibrosis Foundation's Research Development Programs are a network of basic science research centers around the country that brings together leading scientists to pool their talents and advance understanding of the basic science of CF and the complex ways the disease affects different parts of the body.
The Cystic Fibrosis Foundation can help you engage people with cystic fibrosis so that you can incorporate their voices into the decision-making process throughout the development lifecycle of your
The Carolyn and C. Richard Mattingly Leadership in Mental Health Care Award honors those who are committed to the mental health of people with cystic fibrosis.
Cystic Fibrosis Foundation Therapeutics Inc. announced an award of up to $5M to Editas Medicine Inc. to advance potential gene editing approaches for cystic fibrosis.
Researchers' catalog of airway cell types could reveal targets for future genetic therapies